Fierce Pharma
JULY 25, 2024
Three months after bagging FDA approval, Pfizer’s hemophilia B gene therapy has been cleared to expand its reach across the pond. | The company's first gene therapy will debut in Europe as Durveqtix. In the U.S., the drug is approved under the brand name Beqvez.
David Bagga
JULY 25, 2024
Medical Device Sales Academy How to Get Medical Device Sales Jobs with No Experience? Medical device sales become one of the best career options today. More and more people want to crack medical device sales jobs and earn a better living. However, things can seem challenging without prior experience in this field. You must wonder if you […] The post How to Get Medical Device Sales Jobs with No Experience?
Fierce Pharma
JULY 25, 2024
The FDA’s Oncologic Drugs Advisory Committee (ODAC) has unanimously called for a revamp of perioperative clinical trial designs in resectable non-small cell lung cancer (NSCLC) to include assessmen | In a discussion prompted by AstraZeneca's application for Imfinzi, the FDA’s Oncologic Drugs Advisory Committee (ODAC) has unanimously called for a revamp of perioperative clinical trial designs in resectable non-small cell lung cancer.
MedCity News
JULY 25, 2024
Autobahn Therapeutics’ platform technology enables small molecules to selectively hit targets in the brain. In addition to a lead program ready for Phase 2 testing in two types of depression, the startup has a preclinical molecule with potential applications in neuroinflammatory disorders such as multiple sclerosis. The post Fueled With $100M, Autobahn Therapeutics Gears Up for Depression Drug Clinical Trials appeared first on MedCity News.
Speaker: Kevin Burke
AI is reshaping marketing and sales, empowering professionals to work smarter, faster, and more effectively. This webinar will provide a practical introduction to AI, focusing on its current applications, transformative potential, and strategies for successful implementation in your organization. Using real-world examples and actionable insights, we’ll examine how businesses are leveraging AI to increase efficiency, enhance personalization, and drive measurable results.
Fierce Pharma
JULY 25, 2024
With a new chief at the helm and higher profit projections in sight, AbbVie is entering a “new chapter," CEO Robert Michael told analysts Thursday. | Skyrizi's recent ulcerative colitis nod sets it up as a first-line option, while Rinvoq is poised to handle later lines.
MedCity News
JULY 25, 2024
A 10-year partnership between the two organization will standardize patient monitoring hardware and software across 49 Bon Secours Mercy Health hospitals. The post What Bon Secours’ 10-Year Partnership with Philips Hopes to Achieve appeared first on MedCity News.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
MedCity News
JULY 25, 2024
To bring cross-agency clinical leaders together, the FDA should establish a Center of Excellence for Rare Diseases. This would bring together specialized staff and resources from multiple review divisions to leverage their expertise about different bodily systems, trial designs, pharmacology, and other specialized fields. The post To Give Rare Disease Patients Hope, the FDA Must Re-Focus its Efforts appeared first on MedCity News.
Fierce Pharma
JULY 25, 2024
While manufacturing and supply hitches have troubled the rollout of Sanofi’s key respiratory syncytial virus (RSV) drug, the near-term expected approval of a pair of new filling lines is giving the | While manufacturing and supply hitches have troubled the rollout of Sanofi’s key respiratory syncytial virus drug, the near-term expected approval of a pair of new filling lines is giving the French pharma assurance that its AstraZeneca-partnered antibody Beyfortus can breach the billion-dollar thre
MedCity News
JULY 25, 2024
Headway’s $100 million Series D funding round was led by Spark Capital and included participation from Thrive Capital, Accel, a16z and Forerunner Ventures. The post Headway Secures $100M To Expand to MA/Medicaid Members appeared first on MedCity News.
Fierce Pharma
JULY 25, 2024
Among AstraZeneca’s growth drivers with $5 billion or more in peak sales potential, the company is counting on Daiichi Sankyo-partnered Enhertu to chart new territory. | Among AstraZeneca's growth drivers with $5 billion or more in peak sales potential, the company is counting on Daiichi Sankyo-partnered Enhertu to chart new territory. And stalling sales underscore the challenges facing the HER2 drug.
Advertiser: ZoomInfo
Incorporating generative AI (gen AI) into your sales process can speed up your wins through improved efficiency, personalized customer interactions, and better informed decision- making. Gen AI is a game changer for busy salespeople and can reduce time-consuming tasks, such as customer research, note-taking, and writing emails, and provide insightful data analysis and recommendations.
MedCity News
JULY 25, 2024
The good news is that many ACOs have already made the transition to eCQM reporting. Proven best practices are now available. Savvy ACOs will capitalize on efforts to optimize broader quality initiatives under value-based payment over time. The post Electronic Quality Reporting Window Closing on MSSP ACOs: Time for Action Is Now appeared first on MedCity News.
Fierce Pharma
JULY 25, 2024
Just three months after scoring an accelerated FDA approval for Ojemda, Day One Biopharmaceuticals is teaming up with another fellow oncology specialist to grow the medicine's global reach.
pharmaphorum
JULY 25, 2024
There has been a gene therapy on the market for people with the bleeding disorder haemophilia A since 2022, but take-up has been very slow. Pfizer and Sangamo are hoping for a faster trajectory with their experimental treatment.The partners' one-shot giroctocogene fitelparvovec therapy has cleared a phase 3 trial, showing it was better than regular prophylaxis injections with Factor VIII (FVIII) replacement therapies at reducing bleeding episodes, and could now be heading for regulatory review.
Fierce Pharma
JULY 25, 2024
Following last week’s R&D day, argenx continues to demonstrate that its flagship drug, FcRn inhibitor Vyvgart, has plenty of room to grow in its inaugural generalized myasthenia gravis (gMG) in | Following last week’s R&D day, argenx continues to demonstrate that its flagship drug, FcRn inhibitor Vyvgart, has plenty of room to grow in its inaugural generalized myasthenia gravis (gMG) indication.
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
pharmaphorum
JULY 25, 2024
Tune in to the Reverba podcast featuring CEO Cheryl Lubbert as she discusses patient engagement throughout the product lifecycle, sharing insights and strategies for success.
Fierce Pharma
JULY 25, 2024
Large pharma companies are still looking for deals in China. AstraZeneca and Daiichi Sankyo's antibody-drug conjugate star Enhertu experienced a slow quarter. | Large pharma companies are still looking for deals in China. AstraZeneca and Daiichi Sankyo's ADC star Enhertu slowed down. Samsung Biologics' quarterly revenue crossed the 1 trillion Korean won mark for the first time.
pharmaphorum
JULY 25, 2024
Ipsen has signed yet another portfolio-expanding deal – its fifth of the year so far – claiming rights outside the US to a drug for common brain cancer glioma from Day One Biopharmaceuticals.
Pharmaceutical Commerce
JULY 25, 2024
The latest news for pharma industry insiders.
Advertiser: ZoomInfo
In today’s ultra-competitive markets, it’s no longer enough to wait for buyers to show obvious signs of interest. Instead, sales teams must be proactive, identifying and acting on nuanced buyer behaviors — often before prospects are fully ready to make a purchase. In this eBook from ZoomInfo & Sell Better, learn 10 actionable ways to use these buyer signals to transform your sales strategy and close deals faster.
pharmaphorum
JULY 25, 2024
European pharma groups AstraZeneca, Sanofi, and Roche all raise their financial guidance for the year on stronger sales growth.
Copyright Clearance Center
JULY 25, 2024
As AI continues to revolutionize corporate operations, a new collective licensing solution from CCC ensures that both content creators and users can thrive.
pharmaphorum
JULY 25, 2024
NICE clears NHS use of Boehringer's clot-busting drug Metalyse for acute ischaemic stroke, saying it could 'save millions'
Pharmaceutical Technology
JULY 25, 2024
JNJ-2056 is being investigated in the Phase IIb ReTain study which enrols participants who are yet to show Alzheimer’s symptoms.
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
pharmaphorum
JULY 25, 2024
Digital dementia detection specialist Linus Health has expanded its patient care focus with the acquisition of Together Senior Health.
Pharmatutor
JULY 25, 2024
Extensive pharmacological review on Bauhinia racemosa Lam medicinal plant whose leaves are used to make Indian cigarettes (beedi’s) admin Fri, 07/26/2024 - 10:52 Devansh Mehta* M.Pharmacy in Pharmacology, M.B.A. in Pharmaceutical Marketing and Hospital Administration, Founding Medical Writing Director, TRM Writer’s LLP Modipuram, Meerut. *devanshm84@gmail.
PharmaTimes
JULY 25, 2024
Conditions such as Alzheimer’s and Parkinson’s affect over one million people in the UK
pharmaphorum
JULY 25, 2024
FDA's ODAC doesn't vote on AstraZeneca's perioperative Imfinzi regimen in NSCLC but has deep reservations about the design of the phase 3 trial supporting it
Advertiser: ZoomInfo
As prospects define their problem, search for solutions, and even change jobs, they are generating high-value signals that the best go-to-market teams can leverage to close more deals. This is where signal-based selling comes into play. ZoomInfo CEO Henry Schuck recently broke down specific ways to put four key buying signals into action with the experts from 30 Minutes to President’s Club.
PharmaTimes
JULY 25, 2024
The research will help to better understand how this pathway is coordinated in the cell
Pharmacy Times
JULY 25, 2024
Pharmacists could play a major role in answering patient questions and providing counseling about cannabis
Pharmaceutical Technology
JULY 25, 2024
Sandoz launched the biosimilar of J&J’s Stelara in Europe in partnership with Samsung Bioepis to treat psoriasis and Crohn’s disease.
Pharmacy Times
JULY 25, 2024
Adherence and efficacy were both higher in patients with HIV who took twice-yearly lenacapavir compared to those on oral preexposure prophylaxis medication.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Expert insights. Personalized for you.
268 
Let's personalize your content